Erdogan Mehmet, Cetinkalp Sevki, Ozgen Ahmet Gokhan, Saygili Fusun, Berdeli Afig, Yilmaz Candeger
Department of Endocrinology and Metabolism Disease, Ege University Medical School, Izmir, Turkey.
Genet Test Mol Biomarkers. 2012 Feb;16(2):91-4. doi: 10.1089/gtmb.2011.0075. Epub 2011 Aug 23.
Interleukin (IL)-10 is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. IL-10 has met the criteria for an anti-inflammatory and an immunosuppressive cytokine, its activity may be important for clinical outcome of diabetic nephropathy (DN). We aimed at evaluating the relation between the genotypic and allelic frequencies of the IL-10 (-1082G/A) polymorphisms, and their association with the risk to develop DN in the Turkish population.
The (IL)-10 (-1082G/A) genotypes were retrospectively determined in 43 patients with nephropathy and 48 without nephropathy and a control group of 112 healthy individuals. The polymorphisms were analyzed by polymerase chain reaction restriction fragment length polymorphism.
This genotype distribution was different between control subjects and patients with type 2 diabetes in which 24.2% were AA, 75.8% were GA, and 0% were GG (p<0.001). The frequency of the mutant G allele was 36.1% in patients with diabetes nephropathy versus 39.6% in those without nephropathy (p>0.05). The genotype frequencies were AA, 27.9%; GA, 72.1%; and GG, 0% in patients with diabetes with nephropathy versus AA, 20.8%; GA, 79.2%; and GG, 0% in those without nephropathy (p>0.05).
The polymorphisms of IL-10 (-1082G/A) genes were significantly associated with the occurrence of patients with type 2 diabetes. The IL-10 (-1082G/A) genotype and allele frequencies were not different between patients with diabetes with nephropathy and those without nephropathy. Therefore, we conclude that the IL-10 (-1082G/A) gene polymorphism is not associated with the development of DN in Turkish patients with type 2 diabetes.
白细胞介素(IL)-10是一种主要的抗炎细胞因子,在免疫系统调节中起关键作用。IL-10符合抗炎和免疫抑制细胞因子的标准,其活性可能对糖尿病肾病(DN)的临床结局很重要。我们旨在评估IL-10(-1082G/A)多态性的基因型和等位基因频率之间的关系,以及它们与土耳其人群发生DN风险的关联。
回顾性确定了43例肾病患者、48例无肾病患者以及112名健康个体组成的对照组中(IL)-10(-1082G/A)基因型。通过聚合酶链反应限制性片段长度多态性分析多态性。
该基因型分布在对照组与2型糖尿病患者之间存在差异,其中24.2%为AA,75.8%为GA,0%为GG(p<0.001)。糖尿病肾病患者中突变G等位基因的频率为36.1%,无肾病患者中为39.6%(p>0.05)。糖尿病伴肾病患者的基因型频率为AA 27.9%、GA 72.1%、GG 0%,无肾病患者中为AA 20.8%、GA 79.2%、GG 0%(p>0.05)。
IL-10(-1082G/A)基因多态性与2型糖尿病患者的发生显著相关。糖尿病伴肾病患者与无肾病患者之间的IL-10(-1082G/A)基因型和等位基因频率无差异。因此,我们得出结论,IL-10(-1082G/A)基因多态性与土耳其2型糖尿病患者DN的发生无关。